收藏切换
Rapid health technology assessment of romosozumab in the treatment of osteoporosis
收藏切换
Yun ZHANG1, 2, Zhen FENG3, Huiling LI2, Tao WANG3, *
World Clinical Drug | 2025, 46(9) : 958 - 965
Less
收藏切换
World Clinical Drug | 2025, 46(9): 958-965
• Article •
Rapid health technology assessment of romosozumab in the treatment of osteoporosis
Full
Yun ZHANG1, 2, Zhen FENG3, Huiling LI2, Tao WANG3, *
Affiliations
  • 1.School of Pharmacy, Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China
  • 2.Department of Pharmacy, Huai'an First People's Hospital, Huai'an 223300, Jiangsu Province, China
  • 3.Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, Jiangsu Province, China
Published: 2025-09-10 doi: 10.13683/j.wph.2025.09.014
Outline
收藏切换
Objective

To comprehensively evaluate the efficacy, safety and economy of romosozumab in the treatment of osteoporosis(OP) based on rapid health technology assessment(rHTA), to provide a reference for clinical decision-making.

Methods

PubMed, Embase, Cochrane Liarbry, Wanfang, China National Knowledge Infrastructure, VIP database and rHTA-related websites were retrieved. Literature was independently screened according to the inclusion and exclusion criteria respectively, data extraction and quality evaluation were conducted, and descriptive analysis was performed.

Results

A total of 19 articles were included, including 14 systematic reviews or meta-analyses, 3 pharmacoeconomic studies, and 2 rHTA reports. In terms of effectiveness, romosozumab can reduce the risk of fractures in patients with OP, especially vertebral fractures. It can increase bone density, reduce the risk of falls, and improve trabecular bone analysis parameters(P<0.05). In terms of safety, there was no statistically significant difference in the occurrence of adverse events such as drug withdrawal due to adverse reactions, serious adverse reactions, cardiovascular risks, cancer and osteoarthritis in OP patients after treatment with romosozumab(P>0.05), but it did increase the reactions at the injection site. In terms of economy, romosozumab followed by alendronate sodium had a more cost-effectiveness advantage than alendronate sodium alone.

Conclusion

Romosozumab has good efficacy and safety in the treatment of OP and can be regarded as a medium and long-term treatment option.

romosozumab  /  osteoporosis  /  rapid health technology assessment
张赟, 冯振, 李慧玲, 王涛. 罗莫佐单抗治疗骨质疏松的快速卫生技术评估. 世界临床药物, 2025 , 46 (9) : 958 -965 . DOI: 10.13683/j.wph.2025.09.014
Yun ZHANG, Zhen FENG, Huiling LI, Tao WANG. Rapid health technology assessment of romosozumab in the treatment of osteoporosis[J]. World Clinical Drug, 2025 , 46 (9) : 958 -965 . DOI: 10.13683/j.wph.2025.09.014
Year 2025 volume 46 Issue 9
57
11
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.09.014
  • Receive Date:2025-03-07
  • Online Date:2026-11-09
  • Published:2025-09-10
Article Data
Affiliations
History
  • Received:2025-03-07
Funding
Affiliations
    1.School of Pharmacy, Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China
    2.Department of Pharmacy, Huai'an First People's Hospital, Huai'an 223300, Jiangsu Province, China
    3.Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.09.014
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT